GS Paper III · Science & Technology · Biotechnology
💉 Gene Therapy — Fixing the Root Cause of Disease
Replacing Defective Genes · Somatic vs Germline · Viral & Non-Viral Vectors · CRISPR-Cas9 · BIRSA 101 (Sickle Cell) · Casgevy (FDA Approved) · Haemophilia Trial at CMC Vellore · CAR-T Cancer Therapy · Ethical Concerns · Drug Rules 2025 Amendment
💉
What is Gene Therapy?
Altering Genetic Material · Replace / Inactivate / Introduce Genes · Root Cause Treatment
📖 Definition
Gene therapy is a technique that involves altering the genetic material of cells to treat or prevent disease. Instead of treating symptoms with drugs, it targets the root genetic cause inside cells. Three approaches: (1) Replace a mutated gene with a healthy copy, (2) Inactivate a mutated gene that is malfunctioning, (3) Introduce a new gene to help fight the disease. Unlike traditional medicines that must be taken repeatedly, gene therapy can potentially offer a one-time, permanent cure.
Gene Therapy via Viral Vector — An engineered virus carries the functional gene → enters the human cell → delivers the healthy gene into the nucleus → compensates for the defective gene
🏏 Simple Analogy — The "Software Update" for Your Body
Think of your DNA as the operating system of your body. A genetic disease is like a bug in the code — one wrong line causes the whole program to crash. Gene therapy is like sending a software patch (healthy gene) through a USB drive (viral vector) that enters the cell, reaches the nucleus (the computer's processor), and installs the correct code. The "bug" (defective gene) is either overwritten, disabled, or bypassed — and the system starts working normally again. Some patches are temporary (somatic); others could be permanent and heritable (germline — but this is banned for ethical reasons).
🧠 Memory Aid — "RII" = 3 Gene Therapy Approaches
R = Replace the faulty gene with a healthy copy.
I = Inactivate (silence) the malfunctioning gene.
I = Introduce a new gene to fight the disease.
Remember: "RII — Replace, Inactivate, Introduce"
I = Inactivate (silence) the malfunctioning gene.
I = Introduce a new gene to fight the disease.
Remember: "RII — Replace, Inactivate, Introduce"
📋
Types of Gene Therapy
Somatic vs Germline · Autologous vs Allogeneic · Monogenic vs Multigenic
🧍
Somatic Cell Gene Therapy ✅
Targets non-reproductive cells (blood, liver, muscle, etc.). Changes affect only the treated patient — NOT passed to children. Ethically accepted and used in all current approved therapies. Examples: Casgevy (sickle cell), Luxturna (inherited blindness), Zolgensma (spinal muscular atrophy).
🚫
Germline Gene Therapy 🚫
Targets eggs, sperm, or embryos. Changes are inherited by all future generations. Banned in most countries due to ethical and safety concerns. Risk of unintended consequences affecting future humans. He Jiankui scandal (2018): Illegally edited human embryos → imprisoned.
🔄
Autologous (Patient's Own Cells)
Patient's cells extracted → modified in lab → returned. No rejection risk. Personalised but expensive and time-consuming. Example: CAR-T therapy (patient's own T cells engineered).
🤝
Allogeneic (Donor Cells)
Cells from a healthy donor used. Can be "off-the-shelf" — ready-made, cheaper, faster. Risk of immune rejection. Being explored for universal CAR-T cells and stem cell therapies.
🚨 EXAM ALERT — Somatic vs Germline: The Most Tested Distinction!
UPSC 2020 directly tested this: "Genetic changes can be introduced in cells that produce eggs or sperms of a prospective parent" = Germline therapy (TRUE, technically possible, but banned). "A person's genome can be edited before birth at embryonic stage" = Also germline (TRUE, technically possible). UPSC asks whether it's possible (yes) — not whether it's legal or ethical (it's banned). Don't confuse "technically feasible" with "ethically permitted."
🧪
Gene Therapy Methods & Delivery Tools
Viral Vectors · Non-Viral · CRISPR · ZFN · TALENs
| Method | How It Works | Advantages | Limitations |
|---|---|---|---|
| Viral Vectors (AAV, Lentivirus, Retrovirus, Adenovirus) | Engineered viruses carry the therapeutic gene into cells — virus is "disarmed" (can't cause disease) | High efficiency, long-term expression, can target specific tissues | Immune reactions, limited DNA cargo size, risk of insertional mutagenesis (cancer) |
| Non-Viral Methods (Lipid nanoparticles, electroporation) | Physical/chemical methods deliver DNA/RNA without viruses | Safer, no immune response, unlimited cargo size | Lower delivery efficiency, shorter-lasting effect |
| CRISPR-Cas9 | Guide RNA directs Cas9 to cut specific DNA → gene knockout or correction | Simple, cheap, highly efficient, flexible | Off-target edits, delivery challenges |
| Zinc Finger Nucleases (ZFN) | Artificial restriction enzymes engineered to bind & cut specific DNA sequences | Precise gene editing | Complex engineering, lower efficiency than CRISPR |
| TALENs | DNA nucleases fused to TALE DNA-binding proteins | Precise, similar to CRISPR | Technically challenging, slower |
💡 Ex Vivo vs In Vivo Delivery
Ex vivo: Cells removed from patient → modified in lab → returned. More control, safer. Used in CAR-T, some blood disorder therapies.
In vivo: Therapeutic gene delivered directly into the patient's body (injection/infusion). Simpler but harder to control. Used in eye diseases (Luxturna), spinal muscular atrophy (Zolgensma).
In vivo: Therapeutic gene delivered directly into the patient's body (injection/infusion). Simpler but harder to control. Used in eye diseases (Luxturna), spinal muscular atrophy (Zolgensma).
🏥
Applications of Gene Therapy
Genetic Disorders · Cancer · Neurodegenerative Diseases
🩸
Genetic Blood Disorders
Sickle Cell Disease: Casgevy (CRISPR, FDA 2023), BIRSA 101 (India, CSIR-IGIB, 2025). Beta-Thalassemia: Casgevy also approved. Haemophilia A: India's first clinical trial at CMC Vellore. ADA-SCID: "Bubble boy disease" — one of the earliest gene therapy successes.
🎗
Cancer Immunotherapy
CAR-T cell therapy: Patient's T cells engineered to target cancer (NexCAR19 in India, Kymriah/Yescarta in USA). Also: inhibiting tumour growth genes, targeting cancer-specific antigens, blocking blood supply to tumours (anti-angiogenesis).
🧠
Neurodegenerative & Eye Diseases
Luxturna (2017): First FDA-approved gene therapy for inherited blindness (retinitis pigmentosa). Zolgensma (2019): Most expensive drug ever (~₹18 crore/dose) — treats spinal muscular atrophy in infants. Alzheimer's, Parkinson's, ALS — clinical trials using nerve growth factors.
📊 Landmark Gene Therapies — Quick Reference
Casgevy (2023): First CRISPR-based drug. Sickle cell + thalassemia. FDA/EMA/MHRA approved.
BIRSA 101 (2025): India's first indigenous CRISPR therapy. Sickle cell. CSIR-IGIB + Serum Institute. World's most affordable.
NexCAR19 (2023): India's first CAR-T therapy. ImmunoACT + Tata Memorial + IIT Bombay. ~₹30 lakhs.
Luxturna (2017): Inherited blindness. AAV vector delivers RPE65 gene to retina. ~$850,000.
Zolgensma (2019): Spinal muscular atrophy. AAV vector. One-time infusion. ~$2.1 million (most expensive drug ever).
BIRSA 101 (2025): India's first indigenous CRISPR therapy. Sickle cell. CSIR-IGIB + Serum Institute. World's most affordable.
NexCAR19 (2023): India's first CAR-T therapy. ImmunoACT + Tata Memorial + IIT Bombay. ~₹30 lakhs.
Luxturna (2017): Inherited blindness. AAV vector delivers RPE65 gene to retina. ~$850,000.
Zolgensma (2019): Spinal muscular atrophy. AAV vector. One-time infusion. ~$2.1 million (most expensive drug ever).
🇮🇳
India's Gene Therapy Landscape
BIRSA 101 · NexCAR19 · CMC Vellore · Drug Rules 2025 · DCGI Regulation
🧬
BIRSA 101 — CRISPR for Sickle Cell 2025
India's first indigenous CRISPR gene therapy. By CSIR-IGIB + Serum Institute. Named after Birsa Munda (150th birth anniversary). Uses enFnCas9 to correct sickle cell mutation. Target: 1.5–2 crore Indians (tribal communities). Aims to be world's most affordable CRISPR therapy. CDSCO approval expected 2026–27. Goal: Sickle Cell-Free India by 2047.
📜
Drug Rules Amendment (Oct 2025) New
India amended Drug Rules, 1945 to bring all cell and gene therapy products under DCGI control. Covers manufacturing, import, GMP compliance, regulatory approval. First comprehensive framework for gene therapy regulation in India. Also: CMC Vellore conducted India's first human clinical trial of gene therapy for Haemophilia A.
⚠
Challenges & Ethical Concerns
Safety · Ethics · Cost · Delivery · Dual Use
⚡
Safety Risks
Viral vectors can trigger immune reactions. Insertional mutagenesis — gene inserts in wrong location → cancer risk. Off-target effects with CRISPR. Liver toxicity (Intellia paused CRISPR trials Oct 2025). Sarepta's DMD therapy linked to fatal liver failure in some patients.
⚖
Ethical Concerns
Germline editing: Changes heritable forever — "playing God." Designer babies: Enhancement vs treatment line is blurry. Privacy: Genetic data can lead to discrimination. Dual use: Gene editing could create bioweapons. Access: Zolgensma costs ₹18 crore — who decides who gets treated?
💸
Cost & Access Barrier
Zolgensma: ~$2.1M. Luxturna: ~$850K. Casgevy: ~$2.2M. Most patients globally cannot afford these. India's BIRSA 101 and NexCAR19 offer hope for affordable models. But manufacturing complexity + cold chain + GMP requirements keep costs high. Universal access remains the biggest challenge.
📜
Previous Year Questions & Practice MCQs
UPSC Prelims · Gene Therapy · Biotechnology
📜 UPSC CSE Prelims2020
Q. Consider the following statements:
1. Genetic changes can be introduced in the cells that produce eggs or sperms of a prospective parent.
2. A person's genome can be edited before birth at the early embryonic stage.
3. Human induced pluripotent stem cells can be injected into the embryo of a pig.
Which of the above statements is/are correct?
1. Genetic changes can be introduced in the cells that produce eggs or sperms of a prospective parent.
2. A person's genome can be edited before birth at the early embryonic stage.
3. Human induced pluripotent stem cells can be injected into the embryo of a pig.
Which of the above statements is/are correct?
- (a) 1 only
- (b) 2 and 3 only
- (c) 2 only
- (d) 1, 2 and 3 ✅
Explanation: All three are technically possible — that's what UPSC is testing. Statement 1 = germline gene therapy (modifying egg/sperm cells — technically feasible, though banned). Statement 2 = embryonic genome editing (He Jiankui did this in 2018 — proved possible, though illegal). Statement 3 = human-pig chimeras for organ growing (demonstrated in labs). Key trap: UPSC asks "is it possible?" not "is it allowed?"
📜 UPSC CSE Prelims2019
Q. With reference to recent developments in science, which one of the following statements is NOT correct?
- (a) Functional chromosomes can be created by joining DNA segments from cells of different species
- (b) Pieces of artificial functional DNA can be created in laboratories
- (c) A piece of DNA taken from an animal cell can be made to replicate outside a living cell in a laboratory ✅ (This IS correct — PCR does this!)
- (d) Cells taken from plants and animals can undergo cell division in laboratory petri dishes
Explanation: All statements except (a) are correct. Functional chromosomes require centromeres, telomeres, and origins of replication from the SAME species — you can't just join DNA from different species to make a functional chromosome. (b) is correct — synthetic biology creates artificial DNA. (c) is correct — PCR replicates DNA outside cells. (d) is correct — tissue culture. This PYQ tests understanding of gene therapy tools (synthetic DNA, PCR, tissue culture) at a fundamental level.
🎯 Practice MCQs — Click to Answer
Q1. What distinguishes somatic cell gene therapy from germline gene therapy?
- (a) Somatic therapy modifies reproductive cells; germline therapy modifies body cells
- (b) Somatic therapy targets non-reproductive cells (changes NOT inherited); germline therapy targets eggs/sperm/embryos (changes inherited by offspring)
- (c) Somatic therapy is banned worldwide; germline therapy is the standard approach
- (d) Both are identical — the terms are used interchangeably
✅ (b). Somatic = body cells (blood, liver, etc.) → changes affect ONLY the patient → ethically accepted → all approved therapies are somatic. Germline = reproductive cells (eggs, sperm, embryos) → changes INHERITED by all future generations → banned in most countries. Option (a) has them reversed. Option (c) is reversed — somatic is accepted, germline is banned.
Q2. India launched BIRSA 101 in November 2025. It is:
- (a) A mRNA vaccine for COVID-19 targeting tribal populations
- (b) A CAR-T cell therapy for blood cancers developed by ImmunoACT
- (c) India's first indigenous CRISPR-Cas9 gene therapy for sickle cell disease, developed by CSIR-IGIB
- (d) A genome-edited rice variety for drought-prone tribal agricultural regions
✅ (c). BIRSA 101 = India's first CRISPR gene therapy for sickle cell disease. Named after Birsa Munda (150th birth anniversary). Developed by CSIR-IGIB, manufactured by Serum Institute. Option (b) describes NexCAR19 (CAR-T, different therapy). Option (d) describes genome-edited rice (DRR Rice 100/Pusa DST Rice 1). Don't confuse India's biotech milestones!
Q3. Which of the following is the most commonly used gene delivery method in approved gene therapies?
- (a) Viral vectors (AAV, lentivirus) — engineered viruses that carry the therapeutic gene into cells
- (b) Electroporation — using electric pulses to open cell membranes for DNA entry
- (c) CRISPR-Cas9 — cutting DNA and inserting new genes at the break site
- (d) Microinjection — directly injecting DNA into cells using a needle
✅ (a). Viral vectors remain the most widely used delivery method in approved gene therapies (Luxturna uses AAV, Zolgensma uses AAV9, CAR-T uses lentivirus). The virus is "disarmed" — it can enter cells and deliver genes but cannot cause disease. CRISPR is a gene EDITING tool, not primarily a delivery method. Electroporation and microinjection are lab techniques with limited clinical use. The image in this lesson shows exactly how a viral vector delivers the functional gene into a human cell.
Q4. Consider the following statements:
1. Gene therapy has been successfully used only for cancer treatment.
2. Germline gene therapy is banned in most countries because changes are heritable.
3. India amended Drug Rules in 2025 to bring gene therapy products under DCGI regulation.
Which is/are correct?
1. Gene therapy has been successfully used only for cancer treatment.
2. Germline gene therapy is banned in most countries because changes are heritable.
3. India amended Drug Rules in 2025 to bring gene therapy products under DCGI regulation.
Which is/are correct?
- (a) 1 and 2 only
- (b) 1 only
- (c) 2 and 3 only
- (d) 1, 2 and 3
✅ (c) 2 and 3 only. Statement 1 is WRONG — gene therapy treats many diseases beyond cancer: sickle cell disease (Casgevy), inherited blindness (Luxturna), spinal muscular atrophy (Zolgensma), haemophilia, ADA-SCID. Statement 2 is correct — germline editing is banned because changes to eggs/sperm/embryos are passed to ALL future generations. Statement 3 is correct — India's Oct 2025 Drug Rules amendment brought cell and gene therapy products under DCGI control for the first time.
⚡ Quick Revision — Gene Therapy Summary
| Topic | Key Facts |
|---|---|
| Basics | Altering genetic material to treat disease. 3 approaches: Replace, Inactivate, Introduce (RII). Targets root cause, not symptoms. One-time cure potential. |
| Types | Somatic (body cells, NOT inherited, ethically accepted, all approved therapies). Germline (eggs/sperm/embryos, inherited, BANNED). Autologous (patient's cells) vs Allogeneic (donor cells). |
| Tools | Viral vectors (AAV, lentivirus — most used). Non-viral (lipid nanoparticles). CRISPR-Cas9 (simple, cheap). ZFN, TALENs (older, complex). Ex vivo (modify outside body) vs In vivo (deliver directly). |
| Landmark Therapies | Casgevy (2023, CRISPR, sickle cell). BIRSA 101 (2025, India, CRISPR, sickle cell). NexCAR19 (2023, India, CAR-T, blood cancer). Luxturna (2017, blindness). Zolgensma (2019, SMA, ₹18 crore). |
| India | BIRSA 101 (CSIR-IGIB + SII). NexCAR19 (ImmunoACT + TMH + IIT-B). CMC Vellore (Haemophilia A trial). Drug Rules 2025 amendment (DCGI for gene therapy). CrisprBits Bengaluru. |
| Challenges | Safety: immune reactions, insertional mutagenesis, off-target edits, liver toxicity. Ethics: germline editing, designer babies, privacy, bioweapons. Cost: Zolgensma $2.1M. Access inequality. |
🚨 5 UPSC Traps — Gene Therapy:
Trap 1 — "Germline gene therapy is impossible" → WRONG! It is technically possible but ethically banned. He Jiankui proved it can be done (2018). UPSC 2020 tested this — all three statements about genetic modification of embryos/sperm/eggs were TRUE (technically feasible).
Trap 2 — "Gene therapy = CRISPR" → WRONG! CRISPR is ONE tool used in gene therapy. Most approved therapies use viral vectors (AAV, lentivirus), not CRISPR. Casgevy and BIRSA 101 use CRISPR. But Luxturna, Zolgensma, and most CAR-T therapies use viral vectors without CRISPR.
Trap 3 — "Gene therapy only treats genetic diseases" → WRONG! It also treats cancer (CAR-T), infectious diseases (HIV research), and acquired conditions. The field is expanding beyond monogenic (single-gene) disorders to complex multigenic diseases.
Trap 4 — "All gene therapy is permanent" → WRONG! Some therapies provide long-lasting but not always permanent effects. Non-integrating vectors (like AAV) may lose effect over time. Only therapies that integrate into the genome (lentiviral) or edit DNA (CRISPR) tend to be permanent.
Trap 5 — "BIRSA 101 = NexCAR19" → WRONG! These are completely different therapies. BIRSA 101 = CRISPR gene therapy for sickle cell disease (CSIR-IGIB + Serum Institute). NexCAR19 = CAR-T cell therapy for blood cancer (ImmunoACT + Tata Memorial + IIT Bombay). Different technology, different disease, different developers.
Trap 1 — "Germline gene therapy is impossible" → WRONG! It is technically possible but ethically banned. He Jiankui proved it can be done (2018). UPSC 2020 tested this — all three statements about genetic modification of embryos/sperm/eggs were TRUE (technically feasible).
Trap 2 — "Gene therapy = CRISPR" → WRONG! CRISPR is ONE tool used in gene therapy. Most approved therapies use viral vectors (AAV, lentivirus), not CRISPR. Casgevy and BIRSA 101 use CRISPR. But Luxturna, Zolgensma, and most CAR-T therapies use viral vectors without CRISPR.
Trap 3 — "Gene therapy only treats genetic diseases" → WRONG! It also treats cancer (CAR-T), infectious diseases (HIV research), and acquired conditions. The field is expanding beyond monogenic (single-gene) disorders to complex multigenic diseases.
Trap 4 — "All gene therapy is permanent" → WRONG! Some therapies provide long-lasting but not always permanent effects. Non-integrating vectors (like AAV) may lose effect over time. Only therapies that integrate into the genome (lentiviral) or edit DNA (CRISPR) tend to be permanent.
Trap 5 — "BIRSA 101 = NexCAR19" → WRONG! These are completely different therapies. BIRSA 101 = CRISPR gene therapy for sickle cell disease (CSIR-IGIB + Serum Institute). NexCAR19 = CAR-T cell therapy for blood cancer (ImmunoACT + Tata Memorial + IIT Bombay). Different technology, different disease, different developers.
